The effect on bleeding complication occurred by hemostatic agents discontinuation in the percutaneous renal biopsy

The effect on bleeding complication occurred by hemostatic agents discontinuation in the percutaneous renal biopsy - Hemostatic agents discontinuation and bleeding complication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022930

Enrollment

100

Registered

2016-06-28

Start date

2016-06-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney disease

Interventions

Hemostatic agents discontinuation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent percutaneous renal biopsy and underwent abdominal computed tomographic scan after renal biopsy

Exclusion criteria

Exclusion criteria: Patients who were punctured with bilateral kidney with sampling difficulty Patients who received erythrocyte transfusion before confirming hemoglobin concentration in four hours after renal biopsy

Design outcomes

Primary

Measure	Time frame
Hematoma size measured by abdominal computed tomographic scan in 4 or 5 days after the renal biopsy	—

Secondary

Measure	Time frame
change with hemoglobin concentration before the renal bio -psy and 4 hours later and 4 days or 5 days later presence or absence of macroscopic hematuria presence or absence of erythrocyte transfusion presence or absence of angiographic embolization presence or absence of surgical procedure presence or absence of death	—

Countries

Japan

Contacts

Public ContactKensei Yahata

National Hospital Organization Kyoto Medical Center Department of Nephrology

kyahata@kyotolan.hosp.go.jp075-641-9161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026